Replies to post #1528 on Vascular Biogenics Ltd (VBLT)

[staccani]

I agree, the drug holds promise and this is to its dual effect on tumor vasculature and immune system stimulation. I also agree with Oren that combination with pd1 inhibitors represent a compelling opportunity in all cancer types, as pd1 inihibitors break the brakes that the tumor generates to the immune system , whereas VB 111 both makes it more difficult for the tumor to grow and gives more gas to the immune system to destroy it. Their MOA's are evidently complementary.